Bellerophon Therapeutics (BLPH) Reports Q3 Loss of $0.37/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Bellerophon Therapeutics (BLPH) Reports Q3 Loss of $0.37/Share

Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update

March 13, 2017 7:30 AM EDT

WARREN, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2016.

I am pleased with the progress in our ongoing clinical programs to treat pulmonary hypertension in unmet or under-served chronic pulmonary disease areas, stated Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics. Importantly, we are delighted by the FDAs recent agreement with the proposed acceleration of our PAH Phase 3 program, which has the potential to make the INOpulse® therapy available... More